MedTrace Logo

Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

NCT06132035 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2025-02-07

No results posted yet for this study

Summary

This will be a randomized, comparative, parallel, clinical study to assess initial safety and tolerability of CG-P5 peptide eye drops compared to placebo in patients diagnosed with age-related wet macular degeneration

Conditions

  • Age-related Wet Macular Degeneration

Interventions

DRUG

CG-P5 peptide

Patient will instill daily 1 package of CG-P5 peptide eye drops in the study eye \[self-administered\] using the single use tear-off disposable packaging

DRUG

Placebo

Patient will instill daily 1 package of Placebo eye drops in the study eye \[self-administered\] using the single use tear-off disposable packaging

DRUG

Aflibercept Injection [Eylea]

Patient will receiver Eylea® (Aflibercept) intravitreal injection once in a month

Sponsors & Collaborators

  • CBCC Global Research

    collaborator NETWORK

  • Caregen Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • Dr. Yong Ji Chung · Caregen Co. Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-22
Primary Completion
2025-05-31
Completion
2025-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06132035 on ClinicalTrials.gov